Document:

EX-10.75

 Exhibit 10.75 

 
 

 
 PRIVATE AND CONFIDENTIAL 

By Hand 
 July 16, 2014 

Sukhi Jagpal 
 c/o 887 Great Northern Way, Suite 250 

Vancouver BC V5T 4T5 
 Dear Sukhi: 

Re: Retention Bonus 
 In recognition of your work and
contribution to QLT Inc. (the “Company”), we are pleased to confirm that effective upon your acceptance of this letter and subject to the terms described below, you will be eligible to receive a cash retention bonus of CAD $100,000 less
statutory withholdings. The capitalized terms not otherwise defined will have the meaning given to them in the Agreement and Plan of Merger among Auxilium Pharmaceuticals, Inc. (“Auxilium”), the Company and QLT Acquisition Corp. dated
June 25, 2014 (the “Merger Agreement”). 
 This cash retention bonus is payable 90 days following the Closing of the Merger or
February 28, 2015, whichever is later provided that if the Merger Agreement is terminated by either Auxilium or the Company, the full cash retention bonus of CAD $100,000 less statutory withholdings is payable 30 days following the date the
termination is announced or February 28, 2015, whichever is later (the “Payment Date”). 
 The cash retention bonus will be paid provided you
are an active employee of the Company for the full period from July 16, 2014 to the Payment Date, inclusive (the “Bonus Period”). In the event you are not an active employee throughout the Bonus Period (i.e. you are on a leave from
your employment for any reason except approved vacation), then the amount of the retention bonus will be pro-rated by the ratio of the number of days you work during the Bonus Period to the number of working days in the Bonus Period. In addition, if
you are not an active employee on the Payment Date, then the Payment Date of pro-rated retention bonus will be adjusted such that you will receive such payment owing within, but not later than, 30 days of your first day of your return to work. 

Despite the foregoing, in the event that you give notice of resignation from your employment with the Company or just cause exists to terminate your
employment prior to the Payment Date, your participation in and eligibility for the retention bonus will terminate and you will not receive any retention bonus. 

 However, in the event the Company terminates your employment without cause, the Company will pay to you the full
or pro-rated cash retention bonus of CAD $100,000 within 30 days after the termination date. The pro-ration, if applicable, will be based on the ratio of the number of days you worked from July 16, 2014 to the termination date to the number of
working days from July 16, 2014 to the termination date. 
 This letter is in addition to the terms and conditions of your Employment Agreement dated
November 1, 2012 which will continue to apply to your employment. 
 QLT will, acting reasonably, administer and interpret the terms of this letter and
its decisions will be final. 
 Your acknowledgement and agreement with this letter is requested by the end of business on July 18, 2014. Please sign
both copies of this letter where indicated, retain one for your personal files and return the other directly to the attention of Frank Ott. 
 Should you
have any questions regarding this letter or eligibility for the retention bonus, please don’t hesitate to contact Frank. 
 Yours truly, 

QLT Inc. 
  

					
	 /s/ Jeffrey Meckler
	 	 	  	 July 16, 2014

	 Jeffrey Meckler
	 		  	Date
	Director and Chair of Executive Transition Committee	 		  	

 I agree to the terms of the retention bonus as set out above. 

 

					
	 /s/ Sukhi Jagpal
	 	 	  	 July 17, 2014

	 Sukhi Jagpal
	 		  	 DateEXHIBIT 10.1

 

Exhibit
10.1

 

FORM
OF NON-STATUTORY STOCK OPTION AWARD AGREEMENT

 

This
Stock Option Award Agreement (this “Agreement”) is made and entered into as of [DATE] by and between Cortex
Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and [PARTICIPANT NAME] (the “Participant”).

 

Grant
Date: ____________________________________

 

Exercise
Price per Share: __________________________

 

Number
of Option Shares: _________________________

 

Expiration
Date: _________________________________

 

1.Grant
of Option.

 

1.1Grant;
Type of Option. The Company hereby grants to the Participant an option (the “Option”) to purchase the total
number of shares of Common Stock of the Company equal to the number of Option Shares set forth above, at the exercise price set
forth above. The Option is being granted pursuant to the terms of the Company’s 2014 Equity, Equity-Linked and Equity Derivative
Incentive Plan (the “Plan”). The Option is intended to be a Non-Statutory Stock Option and not an Incentive
Stock Option within the meaning of Section 422 of the Internal Revenue Code.

 

1.2Consideration;
Subject to Plan. The grant of the Option is made in consideration of [the services rendered to date and] the services to be
rendered by the Participant to the Company and is subject to the terms and conditions of the Plan. Capitalized terms used but
not defined herein will have the meaning ascribed to them in the Plan.

 

2.Exercise
Period; Vesting.

 

2.1Vesting
Schedule. The Option will become vested and exercisable with respect to [NUMBER] shares on [VESTING SCHEDULE] until the Option
is 100% vested. The unvested portion of the Option will not be exercisable on or after the Participant’s termination of
Continuous Service Status.

 

2.2Expiration.
The Option will expire on the expiration date set forth above, or earlier as provided in this Agreement or the Plan.

 

3.Manner
of Exercise.

 

3.1Election
to Exercise. To exercise the Option, the Participant (or in the case of exercise after the Participant’s death or incapacity,
the Participant’s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an executed
stock option exercise agreement in such form as is approved by the Administrator from time to time (the “Exercise Agreement”),
which shall set forth, inter alia:

 

(a)the
Participant’s election to exercise the Option;

 

(b)the
number of shares of Common Stock being purchased;

 

(c)any
restrictions imposed on the shares; and

 

(d)any
representations, warranties and agreements regarding the Participant’s investment intent and access to information as may
be required by the Company to comply with applicable securities laws.

 

    	 

    	 

    

 

If
someone other than the Participant exercises the Option, then such person must submit documentation reasonably acceptable to the
Company verifying that such person has the legal right to exercise the Option.

 

3.2Payment
of Exercise Price. The entire exercise price of the Option shall be payable in full at the time of exercise in any manner
designated in the Plan.

 

3.3Withholding.
Prior to the issuance of shares upon the exercise of the Option, the Participant must make arrangements satisfactory to the Company
to pay or provide for any applicable federal, state and local withholding obligations of the Company. The Company has the right
to withhold from any compensation paid to a Participant.

 

3.4Issuance
of Shares. Provided that the Exercise Agreement and payment are in form and substance satisfactory to the Company, the Company
shall issue the shares of Common Stock registered in the name of the Participant, the Participant’s authorized assignee,
or the Participant’s legal representative, and shall deliver certificates representing the shares with the appropriate legends
affixed thereto.

 

4.No
Right to Continued Service; No Rights as Shareholder. Neither the Plan nor this Agreement shall confer upon the Participant
any right to be retained in any position, as an Employee or Consultant of the Employer. Further, nothing in the Plan or this Agreement
shall be construed to limit the discretion of the Employer to terminate the Participant’s Continuous Service Status at any
time, with or without Cause. The Participant shall not have any rights as a shareholder with respect to any shares of Common Stock
subject to the Option prior to the date of exercise of the Option.

 

5.Transferability.
The Option may be transferred in accordance with the terms of the Plan upon written approval by the Administrator.

 

6.Change
of Control.

 

6.1Acceleration
of Vesting. [In the event of a Change of Control, notwithstanding any provision of the Plan or this Agreement to the contrary,
the Option shall become immediately vested and exercisable with respect to 100% of the Shares subject to the Option. To the extent
practicable, such acceleration of vesting and exercisability shall occur in a manner and at a time which allows the Participant
the ability to participate in the Change of Control with respect to the shares of Common Stock received.

 

OR

 

Unless
otherwise determined by the Administrator at the time of a Change of Control, a Change of Control shall have no effect on the
Option.]

 

    	2

    	 

    

 

7.Adjustments.
The shares of Common Stock subject to the Option may be adjusted or terminated in any manner as contemplated by Section 10 of
the Plan.

 

8.Tax
Liability and Withholding. Notwithstanding any action the Company takes with respect to any or all income tax, social insurance,
payroll tax, or other tax-related withholding (“Tax-Related Items”), the ultimate liability for all Tax-Related
Items is and remains the Participant’s responsibility and the Company (a) makes no representation or undertakings regarding
the treatment of any Tax-Related Items in connection with the grant, vesting, or exercise of the Option or the subsequent sale
of any shares acquired on exercise; and (b) does not commit to structure the Option to reduce or eliminate the Participant’s
liability for Tax-Related Items.

 

9.Compliance
with Law. The exercise of the Option and the issuance and transfer of shares of Common Stock shall be subject to compliance
by the Company and the Participant with all applicable requirements of federal and state securities laws and with all applicable
requirements of any stock exchange on which the Company’s shares of Common Stock may be listed. No shares of Common Stock
shall be issued pursuant to this Option unless and until any then applicable requirements of state or federal laws and regulatory
agencies have been fully complied with to the satisfaction of the Company and its counsel. The Participant understands that the
Company is under no obligation to register the shares of Common Stock with the Securities and Exchange Commission, any state securities
commission or any stock exchange to effect such compliance.

 

10.Notices.
Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Secretary of
the Company at the Company’s principal corporate offices. Any notice required to be delivered to the Participant under this
Agreement shall be in writing and addressed to the Participant at the Participant’s address as shown in the records of the
Company. Either party may designate another address in writing (or by such other method approved by the Company) from time to
time.

 

11.Governing
Law. This Agreement will be construed and interpreted in accordance with the laws of the State of Delaware without regard
to conflict of law principles.

 

12.Interpretation.
Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company to the Administrator
for review. The resolution of such dispute by the Administrator shall be final and binding on the Participant and the Company.

 

13.Options
Subject to Plan. This Agreement is subject to the Plan as approved by the Company’s shareholders. The terms and provisions
of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between
any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will
govern and prevail.

 

14.Successors
and Assigns. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure
to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement
will be binding upon the Participant and the Participant’s beneficiaries, executors, administrators and the person(s) to
whom the Option may be transferred by will or the laws of descent or distribution.

 

    	3

    	 

    

 

15.Severability.
The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability
of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and
enforceable to the extent permitted by law.

 

16.Discretionary
Nature of Plan. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in its discretion.
The grant of the Option in this Agreement does not create any contractual right or other right to receive any Options or other
Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination
of the Plan shall not constitute a change or impairment of the terms and conditions of the Participant’s employment with
the Company.

 

17.Amendment.
The Committee has the right to amend, alter, suspend, discontinue or cancel the Option, prospectively or retroactively; provided,
that, no such amendment shall adversely affect the Participant’s material rights under this Agreement without the Participant’s
consent.

 

18.No
Impact on Other Benefits. The value of the Participant’s Option is not part of his or her normal or expected compensation
for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.

 

19.Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute
one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic
mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial
appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.

 

20.Acceptance.
The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and understands
the terms and provisions thereof, and accepts the Option subject to all of the terms and conditions of the Plan and this Agreement.
The Participant acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition of the underlying
shares and that the Participant should consult a tax advisor prior to such exercise or disposition.

 

    	4

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

 

	 	CORTEX PHARMACEUTICALS, INC.

  

	 	By:	 
	 	Name: 	 
	 	Title: 	 

 

	 	[EMPLOYEE/DIRECTOR/ CONSULTANT
    NAME]

 

	 	By:	 
	 	Name:	 

 

    	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}]]